Evidence map›Paper›PMID 27499911›Full record

ArticleThe journal of pathology. Clinical research2016

The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study.

George Jour, Lu Wang, Sumit Middha, Ahmet Zehir, Wen Chen, Justyna Sadowska, John Healey, Narasimhan P Agaram, Lisa Choi, Khedoudja Nafa and 1 more

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Case Report:Frontiers in oncology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

George JourDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
Lu WangDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
Sumit MiddhaDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
Ahmet ZehirDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
Wen ChenDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
Justyna SadowskaDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
John HealeyDepartment of Orthopedic Surgery Memorial Sloan Kettering Cancer Center New York NY USA.
Narasimhan P AgaramDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
Lisa ChoiDepartment of Orthopedic Surgery Memorial Sloan Kettering Cancer Center New York NY USA.
Khedoudja NafaDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
Meera HameedDepartment of Pathology Memorial Sloan Kettering Cancer Center New York NY USA.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing <5% of osteosarcomas and <1% of all soft-tissue sarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA and explore potential parameters that may affect outcome. Thirty-two cases were retrieved and histomorphology was reviewed. Clinical history and follow-up were obtained through electronic record review. DNA from formalin-fixed paraffin-embedded (FFPE) tissue was extracted and processed from 27 cases. Genome-wide DNA copy number (CN) alterations and allelic imbalances were analyzed by single nucleotide polymorphism array using Affymetrix OncoScan FFPE Assay. Massive high-throughput deep parallel sequencing was performed using a customized panel targeting 410 cancer genes. Log rank, Fisher's exact test and Cox proportional hazards were used for statistical analysis. In this series of 32 patients (male n = 12, female n = 20), the average age was 66 years (19-93) and median follow up was 24 months (range 6-120 months). Frequent genomic alterations included CN losses in tumour suppressor genes including CDKN2A (70%), TP53 (56%) and RB1 (49%). Mutations affecting methylation/demethylation, chromatin remodeling and WNT/SHH pathways were identified in 40%, 27%, and 27%, respectively. PIK3CA and TERT promoter variant mutations were identified in 11% of the cases. Cases harbouring simultaneous TP53 and RB1 biallelic CN losses were associated with worse overall survival and local recurrence (p = 0.04, p = 0.02, respectively). CDKN2A losses and positive margins were also associated with worse overall survival (p = 0.002; p = 0.03, respectively). Our findings suggest that age above 60, positive margin status, simultaneous biallelic TP53 and RB1 losses and CDKN2A loss are associated with a worse outcome in ESOSA. Comparison between conventional paediatric osteosarcoma and ESOSA shows that, while both share genetic similarities, there are notable dissimilarities and mechanistic differences in the molecular pathways involved in ESOSA.

Indexed as

extraskeletal osteosarcomanext generation sequencingosteosarcomaSNP array

Identifiers

PMID27499911
PMCPMC4858130
OpenAlexW2168113265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.